![WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model](http://prnewswire.vietreader.com/thumb/190x300/2018-01/1515317794_image.png)
WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model
SHANGHAI, Aug. 3, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first half ending...
WuXi AppTec Recognized as a Top-Performing Company on 2026 Dow Jones Best-in-Class World Index
SHANGHAI, May 18, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been selected for the 2026 Dow Jones Best-in-Class World Index (DJ BIC World Index,...
WuXi AppTec Delivers Strong Revenue and Profit Growth in Q1 2026
Total Revenue Reached RMB 12.44 Billion; Revenue from Continuing Operations Up 39.4% YoY Adjusted Non-IFRS Net Profit Up 71.7% YoY to RMB 4.60 Billion Backlog for Continuing Operations Up 23.6% YoY to RMB 59.77 Billion SHANGHAI, April 27, 2026...
WuXi AppTec Receives Double "A" Rating from CDP for Climate Change and Water Security Leadership
SHANGHAI, Jan. 19, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced that it has been recognized on the "A List" for leadership in corporate...
D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs
SHANGHAI, Dec. 10, 2025 /PRNewswire/ -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a $108 million Series B financing round. The...
WuXi AppTec Receives Frost & Sullivan's 2025 Global Company of the Year Recognition in the CRDMO Industry
WuXi AppTec sets new benchmarks in strategic execution and technological advancement, further strengthening its ability to support innovators worldwide as they deliver breakthrough medicines for patients. SAN ANTONIO, Nov. 20, 2025 /PRNewswire/ --...
WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic MoUs with NEOM and Ministry of Health
SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced it has signed two strategic memoranda of understanding (MoUs) with NEOM, the...
WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance
Q3 Total Revenue: RMB12.06 Billion, Up 15.3% YoY; Revenue from Continuing Operations[1] Reached RMB12.04 Billion, Up 19.7% YoY Q1-Q3 Total Revenue: RMB32.86 Billion, Up 18.6% YoY; Revenue from Continuing Operations Reached RMB32.45 Billion, Up 22.5%...
WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets
SHANGHAI, June 18, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that the Science Based...
WuXi AppTec Recognized by Extel 2025 Asia Executive Team Rankings with Top Honors
SHANGHAI, June 16, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been recognized among the Top 10...